GlaxoSmithKline Q3 Results - Q3 Top Pharma Company Earnings Reports

View GlaxoSmithKline's Q3 Earnings Report

FiercePharma says: Emerging markets are paying off for GlaxoSmithKline, but it's pandemic flu that's really accelerating sales. Third-quarter profits jumped by 30 percent to £1.34 billion ($2.18 billion), partly on currency effects, while sales grew 15 percent to £6.76 billion ($11.05 billion). Read more...

Highlights

• Return to sales growth with Q3 turnover +3% CER; +15% sterling
• Continued improvement expected in Q4
• Portfolio diversification and investment in key areas drives return to sales growth: Emerging Markets (+25%); Japan (+19%) and Consumer Healthcare (+8%)
• Further growth expected in Q4 2009 including significant sales of influenza products
• US sales -12% primarily due to continued adverse impact of generic competition

Check out GSK's current estimates from CNN Money

GSK's Website: http://www.gsk.com/

Related Articles:
GSK, Sanofi lobby Irish for HPV shots
As GSK sales move East, so do sales jobs
GSK outgrows 'white pills and western markets'
Cervarix gets CDC nod; Gardasil-for-boys slighted
NICE stiff-arms Glaxo's Tyverb--again